Results 51 to 60 of about 7,263 (276)

Antiemetic research: future directions [PDF]

, 2010
PURPOSE AND METHODS: As a part of reviewing the Multinational Association of Supportive Care in Cancer (MASCC) antiemetic guidelines in Perugia in 2009, an expert group identified directions for future antiemetic research.
Aapro, Matti, Grunberg, Steven, Herrstedt, Jørn, Molassiotis, Alexander, Morrow, Garry, Olver, Ian   +5 more
core   +1 more source

Ocular Administration of Palonosetron in the Prevention of Cisplatin-Induced Nausea and Vomiting

Journal of Pharmacology and Experimental Therapeutics, 2023
Cancer treatments are frequently associated with nausea and vomiting despite greatly improved preventive medication. Administration of antinausea agents as eye drops might provide easy and rapid access to the systemic circulation for prevention of nausea
J. Levijoki, Lasse Saloranta, Johanna Tuunainen, Janne Kaskinoro, Sari Pappinen, S. Nourry, Anne-Marie Bétat, A. Maurin, Maarit Pakarinen, Sari Häkkinen, Johanna Tervapuro, Hertta Pihlasvaara, C. Drieu la Rochelle, H. Joensuu   +13 more
semanticscholar   +1 more source

Reasons for delayed patient discharge following day surgery: a literature review [PDF]

, 2016
NHS Trusts face considerable financial challenges. There is a drive to reduce costs by increasing day surgery rates, thereby reducing the length of post-operative stay.
Alison Rae, Rae, Alison
core   +1 more source

Comparison of the antiemetic efficacy of a combination of midazolam with ramosetron and midazolam with palonosetron for postoperative nausea and vomiting prophylaxis in laparoscopic cholecystectomy

Medicine, 2023
Background: A multimodal therapeutic strategy for preventing postoperative nausea and vomiting (PONV) benefits moderate- and high-risk surgical patients. We compared the efficacy of a combination of midazolam and ramosetron and a combination of midazolam
Jung A Lim, Sungbin Jo, Eunkyung Choi
semanticscholar   +1 more source

Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy [PDF]

, 2010
In this update of our 2005 document, we used an evidence-based approach whenever possible to formulate recommendations, emphasizing the results of controlled trials concerning the best use of antiemetic agents for the prevention of emesis and nausea ...
Ballatori, Enzo, Bria, Emilio, Einhorn, Lawrence H, Espersen, Birgitte, Grunberg, Steven, Herrstedt, Jørn, Hesketh, Paul, Kris, Mark G, Morrow, Gary, Rittenberg, Cynthia, Saito, Mitsue, Tonato, Maurizio   +11 more
core   +1 more source

Palonosetron has superior prophylactic antiemetic efficacy compared with ondansetron or ramosetron in high-risk patients undergoing laparoscopic surgery: a prospective, randomized, double-blinded study [PDF]

Korean Journal of Anesthesiology, 2013
BackgroundPostoperative nausea and vomiting (PONV) continues to be a major problem, because PONV is associated with delayed recovery and prolonged hospital stay.
Sung-Hoon Kim, Jeong-Yeon Hong, Won Oak Kim, Hae Keum Kil, Myong-Hwan Karm, Jai-Hyun Hwang   +5 more
doaj   +1 more source

Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: A Hoosier Cancer Research Network Study [PDF]

, 2016
Purpose A phase III study adding aprepitant to a 5HT3 receptor antagonist (5HT3-RA) plus dexamethasone in germ cell tumor (GCT) patients treated with 5-day cisplatin combination chemotherapy demonstrated a significant improvement in complete response (
Adra, Nabil, Albany, Costantine, Brames, Mary J., Breen, Timothy, Calley, Cynthia, Case-Eads, Somer, Einhorn, Lawrence H., Fausel, Christopher A., Hanna, Nasser H., Hauke, Ralph J., Liu, Ziyue, Picus, Joel   +11 more
core   +1 more source

Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice

Current Cancer Drug Targets, 2022
Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated with many anticancer therapies and can negatively impact patients' quality of life and potentially limit the effectiveness of chemotherapy.
M. Aapro, K. Jordan, F. Scotté, L. Celio, M. Karthaus, E. Roeland   +5 more
semanticscholar   +1 more source

Palonosetron versus ondansetron for prevention of nausea and vomiting after total abdominal hysterectomy under spinal anesthesia with intrathecal morphine: a double-blind, randomized controlled trial

BMC Anesthesiology, 2019
Background Hysterectomy is a widely performed surgery and neuraxial anesthesia with intrathecal morphine provides superior quality of recovery. Postoperative nausea and vomiting (PONV) is a frequent problem with intrathecal morphine use.
Guilherme Oliveira Campos, Marcelo de Jesus Martins, Gabriel Nascimento Jesus, Paulo Roberto Rios de Oliveira, Caio Nogueira Lessa, João Carlos Macêdo Fernandes de Oliveira Junior, Lucas Jorge Santana de Castro Alves, Rodrigo Leal Alves, Norma Sueli Pinheiro Módolo   +8 more
doaj   +1 more source

Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study

BMC Cancer, 2022
The non-inferiority of dexamethasone (DEX) on day 1, with or without low-dose DEX on days 2 and 3, combined with oral NEPA (netupitant/palonosetron), compared with the guideline-consistent use of DEX was demonstrated in cisplatin.
L. Celio, D. Cortinovis, A. Cogoni, L. Cavanna, O. Martelli, S. Carnio, E. Collovà, F. Bertolini, F. Petrelli, A. Cassano, R. Chiari, F. Zanelli, S. Pisconti, I. Vittimberga, A. Letizia, A. Misino, A. Gernone, E. Bonizzoni, S. Pilotto, S. De Placido, E. Bria   +20 more
semanticscholar   +1 more source